Article Text

Download PDFPDF
CASE REPORT
Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
  1. Faisal Inayat1,
  2. Hafeez Ul Hassan Virk2,
  3. Waqas Ullah3,
  4. Qulsoom Hussain4
  1. 1New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
  2. 2Mount Sinai St. Luke's Hospital, Icahn School of Medicine, New York, New York, USA
  3. 3University of Arizona, Tucson, Arizona, USA
  4. 4Shifa International Hospital, Islamabad, Pakistan
  1. Correspondence to Dr Waqas Ullah, waqasullah.dr{at}gmail.com

Summary

Cannabinoid hyperemesis syndrome (CHS) is a rare clinical syndrome characterised by nausea, cyclic vomiting and severe abdominal pain in association with chronic cannabis use. It is often under-recognised or misdiagnosed, resulting in the unnecessary workup and frequent hospitalisations. Long-term treatment of CHS is abstinence from cannabis, but acute symptomatic management has been a struggle for many clinicians. The present report highlights the use of haloperidol as an agent that successfully and safely treats the unrelenting symptoms of CHS.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Acknowledgements The authors acknowledge Dr Abu Hurairah MD for his valuable input in the literature review and case management.

  • Contributors FI and WU did literature search and QH and HUHV wrote case presentation and summary.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.